Insulin glargine/lixisenatide fixed ratio combination

DRUG2 trials

Sponsors

Sanofi

Conditions

Type 2 DiabetesType 2 Diabetes Mellitus

Phase 3

Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

CompletedNCT02058147

SanofiType 2 Diabetes

Start: 2014-02-28End: 2015-06-30Updated: 2017-05-09

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

CompletedNCT02787551

SanofiType 2 Diabetes Mellitus

Start: 2016-07-06End: 2018-11-17Updated: 2022-03-25

Related Papers

Fixed‐ratio combination of insulin glargine plus lixisenatide ( <scp>iGlarLixi</scp> ) improves ß‐cell function in people with type 2 diabetes

Diabetes Obesity and Metabolism2022-03-0812 citations

Efficacy of iGlarLixi on 5-year risk of diabetes-related complications: A simulation study.

2022-01-253 citations

Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results.

2021-12-116 citations

Efficacy of <scp>iGlarLixi</scp> in adults with type 2 diabetes inadequately controlled ( <scp>glycated haemoglobin ≥8%,</scp> ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the <scp>LixiLan‐O</scp> randomized trial

Diabetes Obesity and Metabolism2021-10-064 citations

88-LB: Similar Efficacy and Safety of IGlarLixi When Initiated in Patients with Type 2 Diabetes (T2D) with or without Concomitant Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) Use in a Randomized Controlled Trial (RCT) and Real-World Setting

Diabetes2020-06-011 citations

Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials.

2019-11-263 citations

EFFICACY AND SAFETY OF IGLARLIXI IN HISPANICS AND NON-HISPANIC WHITES WITH TYPE 2 DIABETES.

2019-06-26

149-OR: LixiLan-G: A Randomized Trial Assessing Switching to iGlarLixi vs. Continuation of Daily or Weekly GLP-1RA in T2D Inadequately Controlled by a GLP-1RA and OAD(s)

Diabetes2019-06-011 citations

1139-P: Influence of Screening HbA1c Levels on Glucose Control Achieved when Switching to iGlarLixi in T2D Inadequately Controlled on GLP-1RA and OAD(s)

Diabetes2019-06-011 citations

1146-P: Switching to iGlarLixi vs. Continued Treatment of GLP-1RA: Comparative Analysis by Daily or Weekly GLP-1RAs in the LixiLan-G Trial

Diabetes2019-06-01

Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world

BMJ Open Diabetes Research & Care2019-03-013 citations

Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes.

2019-01-112 citations

Glycemic Target Attainment in Insulin-Naïve Patients with T2D Receiving iGlarLixi

Diabetes2018-06-225 citations

Relationship of Ethnicity to Clinical Outcomes in iGlarLixi-Treated Patients with Type 2 Diabetes

Diabetes2018-06-221 citations

Low incidence of gastrointestinal adverse events over time with a fixed‐ratio combination of insulin glargine and lixisenatide versus lixisenatide alone

Diabetes Obesity and Metabolism2018-06-2021 citations